Oncolytic vaccinia virus with modified B5R gene for the treatment of cancer
AssigneeQueen Mary University of London
InventorsYaohe Wang, Ming Yuan
Life of this patent
Estimating the term…
Abstract
The present invention relates to a vaccinia virus vector comprising a nucleic acid sequence encoding a SCR1−, SCR2−, SCR3−, and SCR4− domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) inserted into the TK gene of the vaccinia virus. The invention also relates to compositions comprising the vaccinia virus vector, methods of treatment using the compositions, medical uses of the compositions and kits comprising the vaccinia virus vector. The invention also relates to a nucleic acid sequence encoding a SCR1−, SCR2−, SCR3−, and SCR4− domain deleted B5R gene (B5R SCR1− SCR2− SCR3− SCR4−) of vaccinia virus.
Claims13
A vaccinia virus vector comprising an intact native B5R gene and a nucleic acid sequence encoding a SCR1−, SCR2−, SCR3−, and SCR4− domain deleted B5R gene (B5R SCR1−SCR2−SCR3−SCR4) having at least 90% sequence identity with the nucleic acid sequence of SEQ ID NO:68 inserted into the TK gene of the vaccinia virus, and wherein the vaccinia virus produces 10- to 30-fold more infectious extracellular enveloped virus (EEV) than a native vaccinia virus while the total replication of the vaccinia virus is not attenuated.
Dependencies are inferred from the claim text.